# Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

> **NCT03158038** · PHASE4 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 300 (actual)

## Conditions studied

- Influenza
- Healthy

## Interventions

- **BIOLOGICAL:** Monovalent Influenza Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03158038
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158038, "Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03158038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*